ACCME Data Shows Scope of CE on ER/LA Opioid REMS
The ACCME has released a data report showing the scope of continuing education activities offered by accredited providers within the ACCME accreditation system in support of the Extended-Release and Long-Acting Opioid Analgesics REMS.
The report shows that 62 accredited CME providers reported 211 REMS-compliant activities educating more than 29,000 learners. The report includes information about the geographic distribution of activities, the activity types, and the numbers and percentages of activities designed and analyzed for changes in competence, performance, or patient outcomes.
The data report is made possible because of the voluntary submission of ER/LA Opioid REMS data by accredited providers into ACCME’s Program and Activity Reporting System (PARS). Launched in 2010, PARS is designed to streamline and support the collection of program and activity data from accredited CME providers. As a service to the CME community and to the FDA, the ACCME modified the Program and Activity Reporting System (PARS) to enable accredited providers to submit information specific to the REMS CME activities they provide.
The US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategies (REMS) is the first REMS to incorporate accredited CME. The centerpiece of the ER/LA Opioid Analgesics REMS is a prescriber education program about the risks of opioid medications as well as safe prescribing and safe use practices. The education is controlled, designed, and delivered by accrediting continuing healthcare education providers.
The ACCME appreciates that the FDA recognizes the value of accredited education and chose to leverage the CE system to carry out this important public health initiative.
Download the PARS Data about ER/LA Opioid REMS CE Activities.
For more information, visit CME in Support of REMS.